ArticleRheumatology international2019

Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.

Philip J Mease et al.PubMed ↗Publisher ↗

No numbers read from the abstract.